T. C. Hohman
About
In The Last Decade
T. C. Hohman
28 papers receiving 983 citations
Peers
Comparison fields: 5 of 105
- Physiology 298
- Cell Biology 286
- Molecular Biology 238
- Clinical Biochemistry 180
- Ophthalmology 151
Countries citing papers authored by T. C. Hohman
This map shows the geographic impact of T. C. Hohman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. C. Hohman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. C. Hohman more than expected).
Fields of papers citing papers by T. C. Hohman
This network shows the impact of papers produced by T. C. Hohman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. C. Hohman. The network helps show where T. C. Hohman may publish in the future.
Co-authorship network of co-authors of T. C. Hohman
This figure shows the co-authorship network connecting the top 25 collaborators of T. C. Hohman. A scholar is included among the top collaborators of T. C. Hohman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. C. Hohman. T. C. Hohman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 16 | |
| 2 | Towards performance improvements in vertical axis wind turbines: Improving wind tunnel simulations of the atmospheric boundary layer and wake interaction studies | 1 |
| 3 | Wind Tunnel Simulation of the Atmospheric Boundary Layer | 1 |
| 4 | Lesion Characteristics and Progression in the Natural History of Geographic Atrophy (GAP)-Study | 1 |
| 5 | Fluorescein Angiographic and OCT Results From an Open–Label, Multicenter, Phase II Study Assessing the Effects of Same–Day Ranibizumab (LucentisTM) and Verteporfin PDT (Visudyne®) | 1 |
| 6 | Preliminary Results From an Open–Label, Multicenter, Phase II Study Assessing the Effects of Same–Day Andministration of Ranibizumab (Lucentis(TM)) and Verteporfin PDT (PROTECT Study) | 10 |
| 7 | 12 | |
| 8 | 106 | |
| 9 | 27 | |
| 10 | 128 | |
| 11 | 78 | |
| 12 | 11 | |
| 13 | Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. | 27 |
| 14 | Na,K-ATPase response to osmotic stress in primary dog lens epithelial cells. | 9 |
| 15 | 79 | |
| 16 | 11 | |
| 17 | 4 | |
| 18 | 45 | |
| 19 | 17 | |
| 20 | 42 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.